RALOXIFENE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

摘要

A pharmaceutical unit dosage form is provided, comprising from 50 to 200 mg of a benzothiophene, preferably raloxifene, or a pharmaceutically-acceptable salt thereof.